news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

"iga nephropathy has a high incidence in china, with a large patient population, which imposes a heavy disease burden on patients, families and society. during treatment, if the source is not suppressed and the cause is not treated, harmful factors will continue to be produced and the development of the disease will be accelerated. therefore, the treatment of iga nephropathy must be causally treated throughout the whole process and as early as possible." director of the department of nephrology, the first affiliated hospital of guangzhou medical universityprofessor xiao jiereminded.

there are currently about 5 million iga nephropathy patients in china, and more than 100,000 new iga nephropathy patients are diagnosed each year. how to delay the progression of iga nephropathy patients, reduce the burden on iga nephropathy patients and society, and promote early diagnosis and treatment to protect patients' renal function has always been a key issue for clinical experts.

high incidence of iga nephropathy and high risk of progression

experts call for early diagnosis and early treatment

"iga nephropathy is a common glomerular disease in the asia-pacific region. in my country, the prevalence of iga nephropathy is not only higher than in europe and the united states, but the risk of progression to renal failure is also greater. according to statistics, compared with european and american countries, the risk of asians progressing to late-stage renal disease is 56% higher."professor wan jianxin, director of the department of internal medicine, the first affiliated hospital of fujian medical universitymentioned in the interview.

professor wan jianxin, director of the department of internal medicine, the first affiliated hospital of fujian medical university

"in addition to the high incidence rate, another characteristic of iga nephropathy is that it is more common in middle-aged and young people. as age increases, the disease will progress to uremia and require dialysis. it not only imposes a burden on the patient's life, but also has a great impact on the economic development of society. therefore, early diagnosis of iga nephropathy is very important." said professor xiao jie.

in addition, according to the recently released data from the national blood purification case information registration system (cnrds), as of the end of december 2023, primary glomerular disease is still the leading cause of end-stage renal disease (esrd) among dialysis patients in mainland my country, accounting for 37.7% of all dialysis patients. my country has the highest incidence of primary glomerular disease in the world, of which iga nephropathy accounts for about 35% to 50%.

it can be seen that the huge number of iga nephropathy patients has brought a heavy medical burden to our society, and it is urgent to improve the diagnosis and treatment of the disease.

mentioning the difficulties and pain points in the diagnosis and treatment of iga nephropathy in my country,professor yang zhenhua, director of the department of nephrology, the first affiliated hospital of guangxi medical universityhe said: "there are regional differences in the diagnosis and treatment levels in china, especially between tertiary hospitals and primary hospitals. because iga nephropathy first requires a renal biopsy to confirm the diagnosis. if a patient with proteinuria is encountered clinically, and the primary doctors are not aware of doing a renal biopsy, they may miss the patient."

professor yang zhenhua, director of the department of nephrology, the first affiliated hospital of guangxi medical university

how to achieve early diagnosis?professor xiao jiesuggestion: "first of all, early detection is necessary. everyone, regardless of health or not, can have a physical examination once a year. a very simple urine routine test can screen out such patients early. once discovered, we must make a clear diagnosis early. patients with proteinuria and hematuria should be considered to have iga nephropathy, and a puncture is required for a clear diagnosis. after a clear diagnosis, timely causal treatment should be carried out to treat the source.

professor xiao jie, director of the department of nephrology, the first affiliated hospital of guangzhou medical university

traditional treatments have serious side effects

experts emphasize that treatment should be carried out throughout the process and as early as possible.

with the advancement of medical technology, the understanding of iga nephropathy is also deepening. regarding the pathogenesis of iga nephropathy,professor wei jiali, director of the department of nephrology, hainan provincial people's hospitalit was explained that the "quadruple hit" theory is currently internationally recognized. abnormalities in mucosal immunity, especially the activation of the ileocecal mucosa of the gastrointestinal tract, release a large amount of β-galactosidase-deficient iga1. iga1 exceeds the metabolic clearance capacity of the liver and then increases in the body. ultimately, β-galactosidase-deficient iga1 is deposited in the kidneys, leading to the occurrence and development of iga nephropathy.

professor wei jiali, director of the department of nephrology, hainan provincial people's hospital

therefore, in the treatment of the disease, "the earlier the treatment threshold is moved, the earlier the production of abnormal pathogenic factor gd-iga1 can be blocked at the source, and the earlier the progression of the disease can be blocked." professor yang zhenhuaemphasize.

however, in the past, the treatment options for iga nephropathy in china mainly included supportive treatment based on renin-angiotensin system (ras) inhibitors and sglt-2 inhibitors, as well as systemic hormone and immunosuppressant treatment.

"however, hormone treatment has many side effects, such as moon face, buffalo hump, obesity, diabetes and osteoporosis, which can easily cause falls and fractures, as well as gastrointestinal ulcers, bleeding and poor sleep. although these drugs can have a certain control effect, they still have many adverse reactions, which prevents many patients from using them or not being able to use them consistently."professor yang zhenhuain the interview, it was mentioned that "therefore, early diagnosis and timely drugs for alleviating the disease are still relatively limited. we urgently need a solution to block the progression of the disease from the source, that is, to treat the cause of the disease."

professor xiao jieit is also emphasized that "in the course of iga nephropathy, if the earliest source is not suppressed and the cause is not treated, it will continue to produce damaging factors and accelerate the development of the disease, so the cause should be treated throughout the treatment process. if the patient develops renal failure and increased proteinuria, the situation will not be so serious and will not progress so quickly. therefore, treatment should be carried out throughout the process and as early as possible."

precise targeting of the intestine to delay kidney function decline

naifencon® opens a new era of causal treatment

the world's first drug for the causal treatment of iga nephropathy, naifon®, was first prescribed in mainland china in may this year and officially entered clinical use, ushering in a new era of causal treatment of iga nephropathy in china. current clinical studies have also shown that as the world's first drug for the causal treatment of iga nephropathy, naifon® can reduce renal function decline by 50%, delay renal function decline by 66% in the chinese population, and is expected to delay the time from disease progression to dialysis or kidney transplantation by 12.8 years.

according toprofessor wan jianxinexplanation: "nafukang® is released in the lymph nodes of the terminal ileum mucosa, inhibiting b lymphocytes from producing pathogenic iga molecules. therefore, it acts on the pathogenic source of iga nephropathy, so it is called causal treatment."

"after the launch of nafukang®, the concept of overall treatment of iga nephropathy has been greatly innovated. clinically, patients have few side effects, including high blood sugar, high blood pressure, bones, digestive system, blood system, and the impact on various organs of the body is significantly reduced compared to systemic oral hormones. in addition, its precise targeted intestinal sustained release and intestinal ph regulation release are very important technical targets. in addition, it has an effect on reducing proteinuria, improving hematuria, delaying the progression of renal function, and stabilizing renal function." professor wei jialiexpress.

"because naifon® is a delayed-release enteric-coated capsule of budesonide, it is not a systemic medication. instead, it is a targeted medication, just like we aim a gun at that place, which is the end of the ileum. it is released here and then absorbed, controlling inflammation locally and reducing damage. therefore, naifon® provides protection for patients in terms of its mechanism of action."professor yang zhenhuaexpress.

it is understood that naifon® is specially developed for patients with iga nephropathy. each capsule contains 4 mg of budesonide. through a special preparation process, budesonide is targeted and released to the mucosa of the terminal ileum (including peyer's lymph nodes). after the capsule is dissolved, the three-layer coated micropellets continuously and stably release budesonide, and the high concentration covers the entire target area, thereby reducing the production of gd-iga1 that induces iga nephropathy, thereby intervening in the upstream stage of the pathogenesis and achieving the effect of treating iga nephropathy. naifon® was approved in china in november 2023 for the treatment of adult patients with primary iga nephropathy at risk of progression. the first prescription was issued in may of this year, officially benefiting patients in mainland china.